Corel Lifecare became interesting because the pitch turned into a competitive process in AgriTech / Aquaculture. The founders walked in with an opening ask of ₹1.2 Crores for 2%, but the bigger signal was that multiple sharks felt there was enough upside to split the deal rather than let one investor take it alone.
The business behind the headline
The useful question here is not whether the startup sounded exciting, but whether it sounded durable.
Corel Lifecare provides science-backed bio-formulations and supplements specifically engineered for Indian water conditions. They solve a massive pain point in the 'Blue Economy'—farmers losing yields due to unpredictable diseases and ineffective, expensive chemical inputs.
How the ask priced the company
The room ultimately priced the company below the founders' opening frame. An ask built around ₹60 Cr moved to ₹15 Cr, which means the investors were willing to engage, but only after marking down the assumptions driving the original number.
This section is less about television drama and more about where the room decided the company was really worth landing.
The room marked the business down from ₹60 Cr to ₹15 Cr, a 75% reset. That usually means investor interest survived, but only after discounting the founders’ original assumptions.
Final terms: ₹1.2 Crores for 8%.
Equity on the table matters too. At 2%, the founders were trading ownership for speed, validation, and access, not just the cheque itself.
The founders asked for a ₹60 Crore valuation. While the Sharks loved the 'farmer-first' approach and the founders' deep domain expertise (12 years in fisheries science), B2B hardware/supplements carry scaling complexities. The Sharks applied a 75% haircut, finalizing a ₹15 Crore valuation to account for the slow, on-ground sales cycle required to build rural trust.
What shifted in the room
The room moved because two investors saw different forms of upside in the same company. That usually means the founders did enough to make the opportunity legible from more than one angle: brand, distribution, category timing, or operator execution.
The most useful signal is usually not the closing line, but the moment the room either tightened around the startup or drifted away from it.
A two-investor outcome often suggests the business made sense from more than one angle. One shark may have liked category or brand, while another saw operational or distribution upside.
Investors involved: Anupam Mittal, Kunal Bahl.
Unlike D2C pitches, there was no hostility here—only rigorous due diligence. The founders wisely traded valuation for the operational and distribution mastery of Anupam and Kunal, recognizing that securing nationwide last-mile delivery is harder than securing capital.
Why this deal matters beyond the show
Strategic win does not mean the founders "won" the market. It means the room found enough evidence to back the company on negotiated terms. The next question is whether Corel Lifecare can turn that room-level conviction into durable execution after the cameras stop rolling.
The lesson here is bigger than the show result. It is about what this deal says regarding leverage, proof, and timing.
STRATEGIC WIN. Corel Lifecare did not “win” the market by getting a cheque. The room simply found enough evidence to back the company on negotiated terms, and execution now has to justify that confidence outside the studio.
- A stretched valuation only works when the supporting evidence is stronger than the founder confidence behind it.
- When more than one investor wants in, founders often protect value by slowing the close, not rushing it.
- The strongest lesson is usually not the pitch theatre, but how clearly the founders defended the business when challenged.
- A stretch valuation is only useful if the founders can defend the assumptions behind it with evidence, not confidence alone.
- When more than one shark wants in, the founders usually win by protecting optionality and resisting the urge to rush the first acceptable term sheet.
- In AgriTech / Aquaculture, category excitement alone is rarely enough. Investors still want evidence that the business can scale without the story collapsing under margin, trust, or repeatability pressure.